Beijing Boyuan Runbu

Beijing Boyuan Runbu Pharmaceutical R&D Co., Ltd. is a Chinese biotechnology company focused on the discovery and early-stage development of novel therapeutics, particularly in the cardiovascular space. Established in April 2024, the company operates as a wholly owned subsidiary of Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. (Buchang Bio), which is a subsidiary of Shandong Buchang Pharmaceuticals. The company's lead program is BC923 (also known as YJH-014), a small interfering RNA (siRNA) therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension. Developed in strategic collaboration with Youjia (Hangzhou) Biomedical Technology Co., Ltd., BC923 received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) in October 2026.